Home > Cardiology > MRA use does not limit empagliflozin benefit in HF with preserved ejection fraction

MRA use does not limit empagliflozin benefit in HF with preserved ejection fraction

Journal
Journal of the American College of Cardiology
Reuters Health - 13/05/2022 - In patients with heart failure with preserved ejection fraction (HFpEF), empagliflozin reduced the combined primary endpoint of cardiovascular (CV) death and HF hospitalization regardless of background use of mineralocorticoid receptor antagonists (MRA), but its effectiveness at reducing HF hospitalizations was more pronounced in MRA nonusers, new data suggest. The findings are from a subanalysis of the EMPEROR-Preserved study, in which patients with chronic HFpEF were randomly assigned to receive the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin or placebo, in addition to background medical therapy. Participants had EF >40%, elevated pro-brain natriuretic peptide (proBNP) and structural heart disease or documented hospitalization for heart failure in the past year. Overall, 91% of participants had hypertension, 86% were receiving beta blockers, and 52% had atrial fibrillation. Previous evaluations of the use of MRAs...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on